替雷利珠单抗联合卡铂与白蛋白紫杉醇在可切除头颈鳞癌新辅助治疗的临床研究
Clinical study on the combination of trastuzumab, carboplatin, and albumin paclitaxel in neoadjuvant therapy for resectable head and neck squamous cell carcinoma
ES评分 0
| DOI |
10.12208/j.ijcr.20250081 |
| 刊名 |
International Journal of Clinical Research
|
| 年，卷(期) |
2025, 9(2) |
| 作者 |
|
| 作者单位 |
1深圳市南山区人民医院 广东深圳,2中山大学孙逸仙纪念医院 广东深圳
|
| 摘要 |
目的 分析替雷利珠单抗联合卡铂与白蛋白紫杉醇在可切除头颈鳞癌新辅助治疗中的价值。方法 取2022-12月至2023-12月可切除头颈鳞癌患者50例（单臂），根据该治疗方法，结合影像学、病理学评价治疗效果。结果 治疗结果及随访结果显示：50例患者的PCR率为62.00%、PPR率为38.00%、无SD与PD病理、复发/转移率为0.00%、总生存率为100.00%、患者各不良反应发生率均不超过20.00%。结论 在可切除头颈鳞癌新辅助治疗中，替雷利珠单抗联合卡铂与白蛋白紫杉醇不仅有较好疗效，且能降低患者癌症转移或复发，提高其生存率。
|
| Abstract |
Objective To analyze the value of the combination of trastuzumab, carboplatin, and albumin paclitaxel in neoadjuvant therapy for resectable head and neck squamous cell carcinoma. Methods A total of 50 patients with resectable head and neck squamous cell carcinoma (single arm) from December 2022 to December 2023 were selected, and the treatment effect was evaluated according to this treatment method, combined with imaging and pathology. Results The results of treatment and follow-up showed that the PCR rate of 50 patients was 62.00%, the PPR rate was 38.00%, the recurrence/metastasis rate was 0.00%, the overall survival rate was 100.00%, and the incidence of adverse reactions in 50 patients was not more than 20.00%. Conclusion In neoadjuvant therapy for resectable head and neck squamous cell carcinoma, the combination of trastuzumab, carboplatin, and albumin paclitaxel not only has good therapeutic effects, but also can reduce cancer metastasis or recurrence and improve survival rates in patients.
|
| 关键词 |
替雷利珠单抗；卡铂；白蛋白紫杉醇；可切除头颈鳞癌；新辅助治疗
|
| KeyWord |
Trelizumab; Carboplatin; Albumin paclitaxel; Resectable head and neck squamous cell carcinoma; Neoadjuvant therapy
|
| 基金项目 |
|
| 页码 |
87-89 |
王杨,刘学,徐明,范松*.
替雷利珠单抗联合卡铂与白蛋白紫杉醇在可切除头颈鳞癌新辅助治疗的临床研究 [J].
国际临床研究杂志.
2025; 9; (2).
87 - 89.